A Multicenter, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects ≥ 1 Month < 16 Years of Age With Epilepsy

Trial Profile

A Multicenter, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects ≥ 1 Month < 16 Years of Age With Epilepsy

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Apr 2018

At a glance

  • Drugs Brivaracetam (Primary)
  • Indications Epilepsy
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors UCB Biopharma
  • Most Recent Events

    • 05 Apr 2018 Planned initiation date changed from 1 Mar 2018 to 1 Apr 2018.
    • 13 Mar 2018 Planned initiation date changed from 1 Feb 2018 to 1 Mar 2018.
    • 15 Feb 2018 Planned End Date changed from 6 Jan 2021 to 1 Feb 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top